

# First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: Mitoriboscins and TPP compounds

Béla Ózsvári<sup>1</sup>, Federica Sotgia<sup>1</sup>, Michael P. Lisanti<sup>1</sup>

<sup>1</sup>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom

**Correspondence to:** Federica Sotgia, Michael P. Lisanti; email: [fsotgia@gmail.com](mailto:fsotgia@gmail.com), [michaelp.lisanti@gmail.com](mailto:michaelp.lisanti@gmail.com)

**Keywords:** cancer stem-like cells (CSCs), mitochondrial inhibitors, treatment failure, breast cancer, metastasis prophylaxis

**Received:** April 25, 2020

**Accepted:** May 14, 2020

**Published:** May 24, 2020

**Copyright:** Ózsvári et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

Cancer stem cells (CSCs) have been proposed to be responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. Therefore, there is an urgent need to identify new drugs that can target and eradicate CSCs. To identify new molecular targets that are unique to CSCs, we previously compared MCF7 2D-monolayers with 3D-mammospheres, which are enriched in CSCs. We observed that 25 mitochondrial-related proteins were >100-fold over-expressed in 3D-mammospheres. Here, we used these 25 proteins to derive short gene signatures to predict distant metastasis (in N=1,395 patients) and tumor recurrence (in N=3,082 patients), by employing a large collection of transcriptional profiling data from ER(+) breast cancer patients. This analysis resulted in a 4-gene signature for predicting distant metastasis, with a hazard ratio of 1.91-fold (P=2.2e-08). This provides clinical evidence to support a role for CSC mitochondria in metastatic dissemination. Next, we employed a panel of mitochondrial inhibitors, previously shown to target mitochondria and selectively inhibit 3D-mammosphere formation in MCF7 cells and cell migration in MDA-MB-231 cells. Remarkably, these five mitochondrial inhibitors had only minor effects or no effect on MDA-MB-231 tumor formation, but preferentially and selectively inhibited tumor cell metastasis, without causing significant toxicity. Mechanistically, all five mitochondrial inhibitors have been previously shown to induce ATP-depletion in cancer cells. Since 3 of these 5 inhibitors were designed to target the large mitochondrial ribosome, we next interrogated whether genes encoding the large mitochondrial ribosomal proteins (MRPL) also show prognostic value in the prediction of distant metastasis in both ER(+) and ER(-) breast cancer patients. Interestingly, gene signatures composed of 6 to 9 MRPL mRNA-transcripts were indeed sufficient to predict distant metastasis, tumor recurrence and Tamoxifen resistance. These gene signatures could be useful as companion diagnostics to assess which patients may benefit most from anti-mito-ribosome therapy. Overall, our studies provide the necessary proof-of-concept, and *in vivo* functional evidence, that mitochondrial inhibitors can successfully and selectively target the biological process of cancer cell metastasis. Ultimately, we envision that mitochondrial inhibitors could be employed to develop new treatment protocols, for clinically providing metastasis prophylaxis, to help prevent poor clinical outcomes in cancer patients.

## INTRODUCTION

Today, breast cancer treatment requires a multi-disciplinary approach, involving an extensive medical

team consisting of specialized surgeons, medical oncologists, oncology nurses, as well as radiologists and radiology technicians, to perform anti-cancer therapy, which consists of tumor excision, chemo- or hormonal-

therapy, as well as radiation therapy. Despite these major advances, many patients still ultimately undergo treatment failure, in the form of tumor recurrence and distant metastasis. Unfortunately, distant metastasis causes premature death, in >90% of cancer patients with treatment failure [1–5]. Therefore, there is a clear need to develop new strategies to prevent cancer cell metastasis.

Local and distant metastases are thought to be caused by a small sub-population of cancer cells, known as cancer stem cells (CSCs) [1–5]. These CSCs are unique, in the sense that they can regenerate tumors in immune-deficient mice, as xenografts, and they undergo anchorage-independent proliferation and the EMT, allowing them to disseminate throughout the body, thereby creating local and distant metastatic lesions, which are largely chemo- and radio-therapy resistant [1–5]. However, it remains largely unknown, what are the precise vulnerabilities of CSCs.

Recently, we identified cancer cell mitochondria as a new promising therapeutic target for the eradication of CSCs [6–8]. New evidence suggests that CSCs have elevated levels of mitochondrial biogenesis, that helps to energetically drive their rapid propagation and anchorage-independent growth [6–10]. In support of this notion, metastatic breast cancer cells in positive lymph nodes, removed from patients, show a significant increase in mitochondrial Complex IV activity, as seen by histochemical- and immunostaining [11, 12].

Importantly, mitochondrial biogenesis is strictly dependent on the function of the mitochondrial ribosome, which consists of both large and small subunits, to effectively carry out the mitochondrial protein translation of 13 key genes that are absolutely required for OXPHOS and mitochondrial ATP production [13]. Interestingly, in eukaryotic cells, mitochondria originally evolved from engulfed aerobic bacteria, an event estimated to have occurred approximately 1.5 billion years ago. Because of this close evolutionary relationship, certain FDA-approved drugs inhibit mitochondrial protein translation as an off-target side effect. For example, Doxycycline (a Tetracycline family member) negatively affects the small mito-ribosome, while Azithromycin (an Erythromycin family member) inhibits the large mito-ribosome. Both Doxycycline and Azithromycin effectively inhibit the anchorage-independent propagation of CSCs, as assessed using the 3D-tumor-sphere assay, in 12 cell lines derived from 8 different cancer types, including breast cancers (MCF7, T47D, MDA-MB-231 and MCF10.DCIS.COM) [13].

Therefore, we proposed that these off-target side-effects could be clinically “re-purposed” as a therapeutic effect.

A recent Phase II clinical trial also showed that Doxycycline treatment (200-mg/day for 2-weeks) of early stage breast cancer patients reduced their CSC tumor load (as assessed by CD44 immuno-staining), between ~17% and ~67%, with a positive response rate approaching nearly 90% [14]. Therefore, inhibition of mitochondrial protein translation may be a new valuable target for eradicating CSCs in patients [14].

To design novel therapeutics to more effectively target the mitochondria, we used the known 3D-structure of the large mammalian mito-ribosome, to perform *in silico* library screening, coupled with phenotypic drug screening, to develop a new family of drug-like compounds, called the Mitoriboscins [15]. Importantly, as predicted, the Mitoriboscins inhibited mitochondrial oxygen consumption rates, resulting in cellular ATP-depletion, and potently inhibited 3D-mammosphere formation, all with an IC-50 in the low micro-molar range [15].

Here, we now show that the Mitoriboscins have only minor effects (23/G4) or no inhibitory effects (24/D4, 24/F9) on tumor growth, but functionally prevent metastatic progression. Quantitatively similar results were obtained with another independent class of mitochondrial inhibitors, namely Butene-1,4-bis-triphenyl-phosphonium (Bis-TPP) and Dodecyl-triphenyl-phosphonium (Dodecyl-TPP) [16, 17]. Bis-TPP and Dodecyl-TPP both contain a TPP moiety, which functions as a chemical signal for mitochondrial targeting [16, 17]. These data provide *in vivo* functional evidence that five mitochondrial inhibitors can successfully and preferentially target the biological process of cancer cell metastasis, without significant toxicity.

## RESULTS

### Cancer stem cell (CSC) based mitochondrial signatures for predicting distant metastasis and tumor recurrence


After a breast cancer diagnosis, most patients undergo surgical resection of the primary tumor and are then subsequently treated with hormone-, chemo- and/or radio-therapy, depending on the breast cancer subtype. However, many patients ultimately experience treatment failure, resulting in tumor recurrence and distant metastasis. Unfortunately, distant metastasis is responsible for the premature deaths in the vast majority of cancer patients, approaching >90% (Figure 1). Therefore, new diagnostics and therapeutics are urgently needed to prevent and treat metastatic disease,

which has been attributed to the existence and resurgence of a small sub-population of cancer cells, known as cancer stem cells (CSCs).

In order to identify new molecular targets that are selectively up-regulated in CSCs, we previously carried out unbiased proteomics analysis on MCF7 cell 2D-monolayers, as directly compared with MCF7 3D-mammospheres, which are known to be highly enriched in CSCs and progenitor cells [6]. As a consequence, we observed that 25 mitochondrial proteins were highly up-regulated by >100-fold, specifically in 3D-mammospheres [6].

Here, we interrogated whether the mRNA transcripts of these mitochondrial proteins show any prognostic value in large numbers of ER(+) human breast cancer patients. Interestingly, we observed that 13 of these 25 gene transcripts showed prognostic value in predicting distant metastasis. We then used these 13 gene transcripts to create a mitochondrial-related gene signature, that effectively predicted distant metastasis in 1,395 patients (HR=1.79; P=3.4e-07). See Supplementary Table 1 and Figure 2.

To optimize its predictive value, we next selected the top 4 gene transcripts, with the largest hazard ratios, to construct a short 4-gene signature, which revealed an increase in prognostic value, related to distant




**Figure 1. Clinical course of cancer therapy: Focus on the causes of treatment failure.** After diagnosis, breast cancer patients undergo surgical resection of the primary tumor and then are treated with a specific therapy (hormone/chemo/radio), depending on the breast cancer subtype and clinical staging. However, a significant number of patients ultimately undergo treatment failure, resulting in tumor recurrence and distant metastasis. Distant metastasis is responsible for the premature deaths of >90% of cancer patients, undergoing treatment failure. This phenomenon has been attributed to the propagation and dissemination of CSCs.

metastasis (HR=1.91; P=2.2e-08). Remarkably, this 4-gene signature was also able to predict tumor recurrence in the same patient population (HR=1.68; P=1.2e-15; Supplementary Table 2 and Figure 3).

Therefore, we conclude that these CSC-based mitochondrial signatures may provide a new prognostic approach for predicting distant metastasis and tumor recurrence in breast cancer patients. Most importantly, these results may also biologically and functionally implicate CSC mitochondria in the process of metastasis and tumor recurrence.

**Mitochondrial inhibitors metabolically target and prevent cancer cell metastasis, without significant toxicity**


To functionally evaluate the role of mitochondria in cancer metastasis, we used a series of mitochondrial inhibitors that were previously developed to specifically target the propagation of CSCs, known as the




**Figure 2. A CSC-based mitochondrial 13-gene signature predicts distant metastasis in ER(+) breast cancer patients.** We used 13 gene transcripts to create a CSC-based mitochondrial-related gene signature, that effectively predicted distant metastasis in N=1,395 patients (HR=1.79; P=3.4e-07). See also Supplementary Table 1. DMFS, distant metastasis free survival.

Mitoriboscins [15]. These inhibitors were developed via *in silico* screening of a library of 45,000 compounds, to identify positive hits that bound to the 3D-structure of the large mitochondrial ribosome [15]. After 880 positive hits were identified, these compounds were then subjected to phenotypic drug screening, using an ATP-depletion assay, and directly validated using the Seahorse Metabolic Flux analyser, to confirm their specificity as *bonafide*

mitochondrial inhibitors [15]. Ultimately, this screening approach led to the identification of three major compounds, known as 23/G4, 24/D4 and 24/F9, which all inhibited 3D-mammosphere formation in MCF7 cells and significantly blocked cell migration in MDA-MB-231 cells, all in the low micro-molar range [15]. The structures of 23/G4, 24/D4 and 24/F9 are shown in Figure 4.



**Figure 3. A CSC-based mitochondrial 4-gene signature predicts distant metastasis and tumor recurrence in ER(+) breast cancer patients.** To optimize its predictive value, we constructed a short 4-gene signature, which revealed an increase in prognostic value, related to distant metastasis (HR=1.91; P=2.2e-08). This 4-gene signature (ACLY, VDAC3, HADH2, COX6B1) was also able to predict tumor recurrence in the same patient population (HR=1.68; P=1.2e-15). See also Supplementary Tables 2 and 3. Therefore, these CSC-based mitochondrial signatures may provide a prognostic approach for predicting treatment failure in breast cancer. DMFS, distant metastasis free survival; RFS, relapse free survival.



**Figure 4. Mitochondrial inhibitors: Mitoriboscins and Bis-1,4-butene-TPP.** The chemical structures of the three Mitoriboscins (23/G4, 24/D4 and 24/F9) and Bis-TTP are shown.

To experimentally evaluate their functional effects *in vivo*, we used MDA-MB-231 cells and the well-established chorio-allantoic membrane (CAM) assay in chicken eggs, to quantitatively measure tumor growth and distant metastasis. An inoculum of  $1 \times 10^6$  MDA-MB-231 cells was added onto the CAM of each egg (day E9) and then eggs were randomized into groups. On day E10, tumors were detectable and they were then treated daily for 8 days with vehicle alone (1% DMSO in PBS) or the three Mitoriboscins compounds. In parallel, we also evaluated the activity of another mitochondrial inhibitor, namely butane-1,4-bis-triphenyl-phosphonium (Bis-TPP), which we identified as an inhibitor of 3D-mammosphere formation in MCF7 cells, with an IC-50 of less than  $0.5 \mu\text{M}$  [16]. It is well-established that the TPP-moiety acts as a chemical signal for mitochondrial targeting [16, 17].

After 8 days of drug administration, on day E18 all tumors were weighed, and the lower CAM was collected to evaluate the number of metastatic cells, as analyzed by qPCR with specific primers for Human Alu sequences.


Figure 5 shows the effects of the three Mitoriboscins (23/G4, 24/D4, 24/F9) and Bis-TPP on MDA-MB-231 tumor growth. Note that none of the four inhibitors tested showed any significant effects on tumor growth, as a result of the 8-day period of drug administration.

However, all four mitochondrial inhibitors showed significant effects on MDA-MB-231 cancer cell metastasis. Figure 6 illustrates that all three Mitoriboscins were clearly effective in inhibiting metastatic progression, although 24/D4 and 24/F9 were the most effective. In addition, Bis-TPP also significantly prevented metastasis.

As 23/G4 was minimally effective at a concentration of  $0.5 \text{ mM}$ , we also tested it at higher concentrations of  $0.75$ ,  $1$  and  $2 \text{ mM}$ . Importantly, our results show that 23/G4, at these concentrations, significantly inhibited both tumor growth (by 40% to 60%; Figure 7) and metastatic progression (by 70-75%; Figure 8). Interestingly, as expected, the effects of 23/G4 on metastasis were significantly more pronounced.

Remarkably, in this series of experiments, little or no embryo toxicity was observed, otherwise tumor growth and cancer metastasis assays could not have been completed (Tables 1–3). Therefore, we conclude that mitochondrial inhibitors can be used experimentally, to preferentially inhibit the initiation of tumor metastasis, without significant toxicity.

Finally, we also tested another more potent mitochondrially-targeted TPP compound, namely Dodecyl-TPP, using low micro-molar concentrations ( $6.25$ - and  $25$ - $\mu\text{M}$ ). Figures 9 and 10 demonstrate that Dodecyl-TPP significantly inhibited tumor growth (by




**Figure 5. Mitochondrial inhibitors have no effect on tumor growth.** MDA-MB-231 cells and the well-established chorio-allantoic membrane (CAM) assay in chicken eggs were used to quantitatively measure tumor growth. An inoculum of  $1 \times 10^6$  MDA-MB-231 cells was added onto the CAM of each egg (on Day E9) and then eggs were then randomized into groups. On day E10, tumors were detectable and they were then treated daily for 8 days with vehicle alone (1% DMSO in PBS) or the four mitochondrial inhibitors. After 8 days of drug administration, on day E18 all tumors were weighed. Note that none of the mitochondrial inhibitors tested had any significant effects on tumor growth. Averages are shown  $\pm$  SEM. NS, not significant.

12% to 40%; Figure 9) and metastatic progression (by 25 to 65%; Figure 10). As predicted, Dodecyl-TPP preferentially targeted metastasis, rather than tumor growth. It is worth noting that Dodecyl-TPP showed some toxicity, but only at 62.5- $\mu$ M, preventing reliable analysis of its effects on tumor growth and metastasis, at this higher concentration (Table 3). However, Dodecyl-TPP showed little or no toxicity at 6.25- and 25- $\mu$ M (Table 3).

### Mito-Ribosome based signatures for predicting distant metastasis and tumor recurrence: Implications as companion diagnostics


Given the functional effects of the Mitoriboscins on metastasis, we next evaluated if the gene mRNA transcripts of the large mitochondrial ribosomal proteins (MRPL) show any prognostic value in ER(+) and ER(-)/basal breast cancer patients.

## Metastasis



**Figure 6. Mitochondrial inhibitor compounds selectively target and prevent cancer metastasis.** MDA-MB-231 cells and the well-established chorio-allantoic membrane (CAM) assay in chicken eggs were used to quantitatively measure spontaneous tumor metastasis. An inoculum of  $1 \times 10^6$  MDA-MB-231 cells was added onto the CAM of each egg (on day E9) and then eggs were then randomized into groups. On day E10, tumors were detectable and they were then treated daily for 8 days with vehicle alone (1% DMSO in PBS) or the four mitochondrial inhibitors. After 8 days of drug administration, the lower CAM was collected to evaluate the number of metastatic cells, as analyzed by qPCR with specific primers for Human Alu sequences. Note that all four mitochondrial inhibitors showed significant effects on MDA-MB-231 metastasis. More specifically, all three Mitoriboscins were clearly effective in inhibiting metastasis, although 24/D4 and 24/F9 were the most effective. In addition, Bis-TPP also significantly prevented metastasis. Averages are shown  $\pm$  SEM. \* $p < 0.05$ ; \*\*\* $p < 0.001$ .

## Tumor Growth



**Figure 7. Effects of the Mitoriboscins 23/G4 on tumor growth.** The Mitoriboscins 23/G4 was tested at higher concentrations of 0.75, 1 and 2 mM. Note that 23/G4, at these concentrations, inhibited tumor growth (by 40% to 60%). Averages are shown  $\pm$  SEM. \*\*\* $p < 0.001$ .

**Table 1. Chick embryo toxicity of Mitoriboscins and Bis-TPP at a concentration of 0.5 mM.**

Group #	Group Description	Total	Alive	Dead	% Alive	% Dead
1	Neg. Ctrl.	18	16	2	88.89	11.11
2	23/G4	10	7	3	70	30
3	24/D4	12	12	0	100	0
4	24/F9	10	8	2	80	20
5	Bis-TPP	12	7	5	58.33	41.67

**Table 2. Chick embryo toxicity of Mitoriboscins 23/G4 at higher concentrations.**


Group #	Group Description	Total	Alive	Dead	% Alive	% Dead
1	Neg. Ctrl.	17	12	5	70.59	29.41
2	23/G4 [0.75 mM]	14	10	4	71.43	28.57
3	23/G4 [1 mM]	15	12	3	80	20
4	23/G4 [2 mM]	15	10	5	66.67	33.33

**Table 3. Chick embryo toxicity of Dodecyl-TPP.**

Group #	Group Description	Total	Alive	Dead	% Alive	% Dead
1	Neg. Ctrl.	18	13	5	72.22	27.78
2	d-TPP [6.25 μM]	19	13	6	68.42	31.58
3	d-TPP [25 μM]	19	13	6	68.42	31.58
4	d-TPP [62.5 μM]	19	3	16	15.79	84.21

In ER(+) breast cancer, a 9-gene mito-ribosome signature was able to effectively predict distant metastasis in N=1,395 patients (HR=1.59; P=5e-05) and tumor recurrence in N=3,082 patients (HR=1.71; P<1e-16) (See Supplementary Tables 4 and 5; Figure 11). Importantly, a closely related mito-ribosome signature was also

able to predict treatment failure in a sub-set of ER(+) patients undergoing Tamoxifen treatment, which resulted in distant metastasis (N=618 patients; HR=2.16; P=1.7e-05) and tumor recurrence (N=799 patients; HR=3.45; P=1.6e-08) (Supplementary Tables 6 and 7; Figure 12).




**Figure 8. Effects of the Mitoriboscins 23/G4 on cancer metastasis.** The Mitoriboscins 23/G4 was tested at higher concentrations, namely 0.75, 1 and 2 mM. Note that 23/G4, at these concentrations, significantly inhibited metastasis (by 70-75%). Interestingly, the effects of 23/G4 on metastasis were significantly more pronounced than its effects on tumor growth. Averages are shown  $\pm$  SEM. \*\*\*p<0.001.

In ER(-)/basal breast cancer, a distinct 6-gene mito-ribosome MRPL signature was also able to effectively predict distant metastasis in N=145 patients (HR=2.95; P=0.0018) and tumor recurrence in N=360 patients (HR=2.19; P=1.9e-06), as well as overall survival in N=153 patients (HR=3.17; P=0.00033) (Supplementary Table 8; Figures 13 and 14).

In summary, these short mito-ribosome gene signatures may also be useful as companion diagnostics to assess which patient populations may benefit most from the administration of the Mitoriboscins compounds.

## DISCUSSION


Current thinking indicates that CSCs are the etiological cause of treatment failure in most cancer patients, as they are the cellular drivers of tumor recurrence, metastasis and drug-resistance [1–5]. As a consequence, new therapeutic approaches are needed to effectively eliminate CSCs. Our previous studies identified CSC mitochondria as a potential new therapeutic target. More specifically, we experimentally observed that



**Figure 9. Effects of Dodecyl-TPP on tumor growth.** Dodecyl-TPP, another more potent mitochondrially-targeted TPP compound, was tested using low micro-molar concentrations (6.25- and 25- $\mu$ M). Note that Dodecyl-TPP significantly inhibited tumor growth (by 12% to 40%). Averages are shown  $\pm$  SEM. \* $p$ <0.05; \*\*\* $p$ <0.001. The structure of Dodecyl-TPP (d-TPP) is also shown. Note the 12-carbon alkyl-chain attached to the lipophilic cation, triphenyl-phosphonium (TPP).

MCF7-derived 3D-mammospheres are specifically enriched in mitochondrial proteins; 25 mitochondrial proteins showed greater than 100-fold over-expression, while 9 of these proteins were infinitely up-regulated, as compared with 2D-monolayers [6]. In this report, we used these proteomic data as possible candidates to generate short mitochondrial gene signatures that could be employed as prognostic tools to predict distant metastasis (in N=1,395 patients) and tumor recurrence (in N=3,082 patients), in a large collection of ER(+) breast cancer patients. For example, we developed a 4-gene signature for predicting distant metastasis, resulting in a hazard ratio of 1.91-fold (P=2.2e-08). This clinical evidence supports the idea that CSC mitochondria may play a critical functional role in the metastatic dissemination of cancer cells.


To further test this hypothesis experimentally, we next employed a well-established animal model, namely the chorio-allantoic membrane (CAM) in chicken eggs, to test a series of mitochondrial inhibitors. These mitochondrial inhibitors, including the Mitoriboscins, have been previously described to effectively inhibit 3D-mammosphere formation in MCF7 cells and cell migration in MDA-MB-231 cells. All five of these



**Figure 10. Effects of Dodecyl-TPP on cancer metastasis.** Dodecyl-TPP was tested using low micro-molar concentrations (6.25- and 25- $\mu$ M). Note that Dodecyl-TPP significantly inhibited metastasis (by 25% to 65%). Averages are shown  $\pm$  SEM. \* $p$ <0.05; \*\*\* $p$ <0.001. Importantly, little or no toxicity was observed for Dodecyl-TPP at 6.25- and 25- $\mu$ M (Table 3). The structure of Dodecyl-TPP (d-TPP) is also shown.

## Large-Mito-Ribosome-Genes

ER(+)




**Figure 11. A large mito-ribosome 9-gene signature predicts metastasis and recurrence in ER(+) breast cancer patients.** A 9-gene mito-ribosome signature effectively predicts distant metastasis in N=1,395 patients (HR=1.59; P=5e-05) and tumor recurrence in N=3,082 patients (HR=1.71; P<1e-16). See Supplementary Tables 4 and 5. DMFS, distant metastasis free survival; RFS, relapse free survival.

## Large-Mito-Ribosome-Genes

Tamoxifen-Treated


Patients



**Figure 12. A large mito-ribosome gene signature predicts metastasis and recurrence in ER(+) breast cancer patients, treated with Tamoxifen.** A mito-ribosome signature predicts treatment failure in a sub-set of ER(+) patients undergoing Tamoxifen treatment, which resulted in distant metastasis (N=618 patients; HR=2.16; P=1.7e-05) and tumor recurrence (N=799 patients; HR=3.45; P=1.6e-08). See also Supplementary Tables 6 and 7. DMFS, distant metastasis free survival; RFS, relapse free survival.

## Large-Mito-Ribosome-Genes


ER(-)/Basal Sub-type



**Figure 13. A large mito-ribosome gene signature predicts distant metastasis and tumor recurrence in ER(-)/basal breast cancer patients.** In ER(-)/basal breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict distant metastasis in N=145 patients (HR=2.95; P=0.0018) and tumor recurrence in N=360 patients (HR=2.19; P=1.9e-06). See also Supplementary Table 8.

## Large-Mito-Ribosome-Genes


ER(-)/Basal Sub-type



**Figure 14. A large mito-ribosome gene signature predicts overall survival in ER(-)/basal breast cancer patients.** In ER(-)/basal breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict overall survival in N=153 patients (HR=3.17; P=0.00033). OS, overall survival.

mitochondrial inhibitors selectively prevented MDA-MB-231 tumor cell metastasis, but had only minor effects or no effect on tumor formation. More specifically, we have previously shown that these mitochondrial inhibitors successfully induce ATP-depletion in cancer cells, by targeting mitochondrial protein translation and/or OXPHOS activity [15–17]. Our current studies provide the necessary *in vivo* functional evidence, that mitochondrial inhibitors can successfully prevent cancer metastasis. These findings could have important clinical implications, for ultimately preventing treatment failure in breast cancer patients, via metastasis prophylaxis (Figure 15).

Since the Mitoriboscins were originally engineered to inhibit the large mitochondrial ribosome [15], we also focused on whether the large mitochondrial ribosomal gene transcripts (MRPL) have any prognostic value, for predicting distant metastasis in ER(+) breast cancer patients. Importantly, signatures containing MRPL gene transcripts were effective in predicting metastasis, recurrence and Tamoxifen-resistance. Similar results were also obtained in ER(-) breast cancer patients. As a consequence of the success of this approach, these MRPL gene signatures may ultimately be useful as new companion diagnostics, to guide decisions to determine which patients would benefit from anti-mito-ribosome therapy.



**Figure 15. Metastasis prophylaxis: Clinical implications of mitochondrial inhibitors for the prevention of treatment failure and cancer metastasis.** Based on our current results, that mitochondrial inhibitors can selectively prevent metastasis, we suggest that these findings could be applied clinically to help prevent treatment failure in breast cancer patients.

## MATERIALS AND METHODS

### Materials

MDA-MB-231 cells, a human breast cancer cell line, were obtained from the American Type Culture Collection (ATCC). Mitoriboscins (23/G4, 24/D4, 24/F9), Butene-1,4-bis-triphenyl-phosphonium (Bis-TPP), and Dodecyl-TPP, were all as we previously described [15–17].

### Kaplan-Meier (K-M) analyses

To perform K-M analysis on gene transcripts, we used an open-access online survival analysis tool to interrogate publically available microarray data from up to 3,951 breast cancer patients (18). This allowed us to determine their prognostic value. For this purpose, we primarily analyzed data from ER(+)-s and ER(-)-basal patients. Biased array data were excluded from the analysis. This allowed us to identify mitochondrial gene transcripts, with significant prognostic value. Hazard-ratios were calculated, at the best auto-selected cut-off, and p-values were calculated using the Log-rank test and plotted in R. K-M curves were also generated online using the K-M-plotter (as high-resolution TIFF files), using univariate analysis: <https://kmplot.com/analysis/index.php?p=service&cancer=breast>.

This approach allowed us to directly perform *in silico* validation of these mitochondrial biomarker candidates. The multi-gene classifier function of the program was used to test the prognostic value of short mitochondrial gene signatures, using the mean expression of the selected probes. The latest 2020 version of the database was utilized for all these analyses.

### Assays for tumor growth, metastasis and embryo toxicity

#### Preparation of chicken embryos

Fertilized White Leghorn eggs were incubated at 37.5°C with 50% relative humidity for 9 days. At that moment (E9), the chorioallantoic membrane (CAM) was dropped down by drilling a small hole through the eggshell into the air sac, and a 1 cm<sup>2</sup> window was cut in the eggshell above the CAM (19-23).

#### Amplification and grafting of tumor cells

The MDA-MB-231 tumor cell line was cultivated in DMEM medium supplemented with 10% FBS and 1% penicillin/streptomycin. On day E9, cells were detached with trypsin, washed with complete medium and suspended in graft medium. An inoculum of 1 X 10<sup>6</sup> cells was added onto the upper CAM of each egg (E9) and then eggs were randomized into groups [19–23].

### **Tumor growth assays**

At day 18 (E18), the upper portion of the CAM was removed from each egg, washed in PBS and then directly transferred to paraformaldehyde (fixation for 48 h) and weighed [19–23]. For tumor growth assays, at least 8 tumor samples were collected and analysed per group ( $n \geq 8$ ).

### **Metastasis assays**

On day E18, a 1 cm<sup>2</sup> portion of the lower CAM was collected to evaluate the number of metastatic cells in 8 samples per group ( $n=8$ ). Genomic DNA was extracted from the CAM (commercial kit) and analyzed by qPCR with specific primers for Human Alu sequences. Calculation of Cq for each sample, mean Cq and relative amounts of metastases for each group are directly managed by the Bio-Rad® CFX Maestro software. A one-way ANOVA analysis with post-tests was performed on all the data [19–23].

### **Embryo tolerability assays**

Before each administration, the treatment tolerability was evaluated by scoring the number of dead embryos. This approach is summarized schematically in Supplementary Figures 1 and 2.

## **ACKNOWLEDGMENTS**

We are grateful to Rumana Rafiq, for her kind and dedicated assistance, in keeping the Translational Medicine Laboratory at the University of Salford running very smoothly. We would like to thank the Foxpoint Foundation (Canada) and the Healthy Life Foundation (UK) for their philanthropic donations towards new equipment and infrastructure, in the Translational Medicine Laboratory at the University of Salford. We are thankful to Inovotion, Inc. (Grenoble, France), for independently performing the tumor growth and metastasis studies, using the CAM assay, as well as evaluating chicken embryo toxicity, through a research contract with Lunella Biotech, Inc (Ottawa, Canada).

## **CONFLICTS OF INTEREST**

MPL and FS hold a minority interest in Lunella Biotech, Inc.

## **FUNDING**

This work was supported by research grant funding, provided by Lunella Biotech, Inc.

## **REFERENCES**

1. Sotgia F, Ozsvari B, Fiorillo M, De Francesco EM, Bonuccelli G, Lisanti MP. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. *Cell Cycle*. 2018; 17:2091–100. <https://doi.org/10.1080/15384101.2018.1515551> PMID:30257595
2. De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. *Biochem J*. 2018; 475:1611–34. <https://doi.org/10.1042/BCJ20170164> PMID:29743249
3. Martinez-Outschoorn UE, Peiris-Pagès M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. *Nat Rev Clin Oncol*. 2017; 14:11–31. <https://doi.org/10.1038/nrclinonc.2016.60> PMID:27141887
4. Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. *Breast Cancer Res*. 2016; 18:55. <https://doi.org/10.1186/s13058-016-0712-6> PMID:27220421
5. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. *Int J Biochem Cell Biol*. 2012; 44:2144–51. <https://doi.org/10.1016/j.biocel.2012.08.022> PMID:22981632
6. Lamb R, Harrison H, Hult J, Smith DL, Lisanti MP, Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition. *Oncotarget*. 2014; 5:11029–37. <https://doi.org/10.18632/oncotarget.2789> PMID:25415228
7. Farnie G, Sotgia F, Lisanti MP. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. *Oncotarget*. 2015; 6:30472–86. <https://doi.org/10.18632/oncotarget.5401> PMID:26421710
8. Lamb R, Bonuccelli G, Ozsvári B, Peiris-Pagès M, Fiorillo M, Smith DL, Bevilacqua G, Mazzanti CM, McDonnell LA, Naccarato AG, Chiu M, Wynne L, Martinez-Outschoorn UE, et al. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: understanding Wnt/FGF-driven anabolic signaling. *Oncotarget*. 2015; 6:30453–71. <https://doi.org/10.18632/oncotarget.5852> PMID:26421711
9. De Luca A, Fiorillo M, Peiris-Pagès M, Ozsvari B, Smith DL, Sanchez-Alvarez R, Martinez-Outschoorn UE, Cappello AR, Pezzi V, Lisanti MP, Sotgia F. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. *Oncotarget*. 2015; 6:14777–95. <https://doi.org/10.18632/oncotarget.4401> PMID:26087310

10. Peiris-Pagès M, Oszvári B, Sotgia F, Lisanti MP. Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: mito-stemness and ribo-stemness features. *Aging* (Albany NY). 2019; 11:4801–35.  
<https://doi.org/10.18632/aging.102054>  
PMID:[31311889](https://pubmed.ncbi.nlm.nih.gov/31311889/)
11. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the “reverse warburg effect” in positive lymph node tissue. *Cell Cycle*. 2012; 11:1445–54.  
<https://doi.org/10.4161/cc.19841> PMID:[22395432](https://pubmed.ncbi.nlm.nih.gov/22395432/)
12. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S, Tsigos A, Ertel A, Pestell RG, Broda P, Minetti C, Lisanti MP, Sotgia F. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. *Cell Cycle*. 2011; 10:4047–64.  
<https://doi.org/10.4161/cc.10.23.18151>  
PMID:[22134189](https://pubmed.ncbi.nlm.nih.gov/22134189/)
13. Lamb R, Oszvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. *Oncotarget*. 2015; 6:4569–84.  
<https://doi.org/10.18632/oncotarget.3174>  
PMID:[25625193](https://pubmed.ncbi.nlm.nih.gov/25625193/)
14. Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli M, Sotgia F, Lisanti MP, Naccarato AG. Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: a clinical pilot study. *Front Oncol*. 2018; 8:452.  
<https://doi.org/10.3389/fonc.2018.00452>  
PMID:[30364293](https://pubmed.ncbi.nlm.nih.gov/30364293/)
15. Oszvari B, Fiorillo M, Bonuccelli G, Cappello AR, Frattaruolo L, Sotgia F, Trowbridge R, Foster R, Lisanti MP. Mitoriboscins: mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. *Oncotarget*. 2017; 8:67457–72.  
<https://doi.org/10.18632/oncotarget.19084>  
PMID:[28978045](https://pubmed.ncbi.nlm.nih.gov/28978045/)
16. Oszvari B, Sotgia F, Lisanti MP. Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs). *Aging* (Albany NY). 2018; 10:229–40.  
<https://doi.org/10.18632/aging.101384>  
PMID:[29466249](https://pubmed.ncbi.nlm.nih.gov/29466249/)
17. De Francesco EM, Ószvári B, Sotgia F, Lisanti MP. Dodecyl-TPP targets mitochondria and potently eradicates cancer stem cells (CSCs): synergy with FDA-approved drugs and natural compounds (Vitamin C and berberine). *Front Oncol*. 2019; 9:615.  
<https://doi.org/10.3389/fonc.2019.00615>  
PMID:[31440463](https://pubmed.ncbi.nlm.nih.gov/31440463/)
18. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res Treat*. 2010; 123:725–31.  
<https://doi.org/10.1007/s10549-009-0674-9>  
PMID:[20020197](https://pubmed.ncbi.nlm.nih.gov/20020197/)
19. Alsamri H, El Hasasna H, Al Dhaheri Y, Eid AH, Attoub S, Iratni R. Carnosol, a natural polyphenol, inhibits migration, metastasis, and tumor growth of breast cancer via a ROS-dependent proteasome degradation of STAT3. *Front Oncol*. 2019; 9:743.  
<https://doi.org/10.3389/fonc.2019.00743>  
PMID:[31456939](https://pubmed.ncbi.nlm.nih.gov/31456939/)
20. Nascimento BF, Laranjo M, Pereira NA, Dias-Ferreira J, Piñeiro M, Botelho MF, Pinho E Melo TM. Ring-fused diphenylchlorins as potent photosensitizers for photodynamic therapy applications: in vitro tumor cell biology and in vivo chick embryo chorioallantoic membrane studies. *ACS Omega*. 2019; 4:17244–50.  
<https://doi.org/10.1021/acsomega.9b01865>  
PMID:[31656898](https://pubmed.ncbi.nlm.nih.gov/31656898/)
21. Gilson P, Couvet M, Vanwonterghem L, Henry M, Vollaire J, Baulin V, Werner M, Orłowska A, Jossierand V, Mahuteau-Betzer F, Lafanechère L, Coll JL, Busser B, Hurbin A. The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo. *Biochem Pharmacol*. 2019; 160:1–13.  
<https://doi.org/10.1016/j.bcp.2018.12.004>  
PMID:[30529691](https://pubmed.ncbi.nlm.nih.gov/30529691/)
22. El Hasasna H, Saleh A, Al Samri H, Athamneh K, Attoub S, Arafat K, Benhalilou N, Alyan S, Viallet J, Al Dhaheri Y, Eid A, Iratni R. Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NFκB and nitric oxide pathways. *Sci Rep*. 2016; 6:21144.  
<https://doi.org/10.1038/srep21144>  
PMID:[26888313](https://pubmed.ncbi.nlm.nih.gov/26888313/)
23. Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Viallet J, Saleh A, Al Agha H, Eid A, Iratni R. Anti-metastatic and anti-tumor growth effects of origanum majorana on highly metastatic human breast cancer cells: inhibition


of NFκB signaling and reduction of nitric oxide production. PLoS One. 2013; 8:e68808.

<https://doi.org/10.1371/journal.pone.0068808>


PMID:[23874773](https://pubmed.ncbi.nlm.nih.gov/23874773/)

## SUPPLEMENTARY MATERIALS

### Supplementary Figures



**Supplementary Figure 1. Summary: The Chorio-allantoic Membrane (CAM) Method.** Fertilized White Leghorn eggs were as used the xenograft host for growing human MDA-MB-231 cells to measure i) tumor growth (weight), ii) metastatic invasion/progression (by qPCR with specific primers for Human Alu sequences) and iii) drug toxicity (by evaluating chicken embryo viability). MDA-MB-231 cells were implanted on embryonic day 9 (E9). Then, tumor growth and metastasis were evaluated on embryonic day 18 (E18). Treatments were administered for 8 days, from E10 till E17. Using this approach, the efficacy and toxicity of five mitochondrial inhibitors were evaluated, in an *in vivo* setting: Mitoriboscins (23/G4, 24/D4, 24/F9) and TPP compounds (Bis-TPP and Dodecyl-TPP). See *Materials & Methods* for specific details.



**Supplementary Figure 2. Measuring Distant Metastasis with the CAM Method.** Spontaneous metastasis from the primary tumor located in the Upper CAM was measured by quantitating the amount of metastatic cells that accumulated in the Lower CAM region, after a period of 9 days, post-tumor cell implantation, using qPCR analysis. Importantly, metastatic dissemination, from the Upper CAM to the Lower CAM, requires cell migration, invasion, intravasation, extravasation and the formation of secondary lesions.

## Supplementary Tables

**Supplementary Table 1. Distant metastasis signature (13 genes): prognostic value of mitochondrial-related proteins up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (DMFS/ER(+)/N=1,395/>240-months).**

Probe	Symbol	HR (DMFS)	Log-rank test
201128_s_at	ACLY	1.72	3.1e-05
208845_at	VDAC3	1.66	1.2e-05
202282_at	HADH2	1.58	7.2e-05
201441_at	COX6B1	1.53	0.00017
201322_at	ATP5B	1.43	0.0016
218440_at	MCCC1	1.40	0.0054
218275_at	SLC25A10	1.37	0.0048
205217_at	TIMM8A	1.37	0.0072
200789_at	ECH1	1.35	0.0092
212186_at	ACACA	1.34	0.031
200690_at	HSPA9	1.29	0.046
217720_at	CHCHD2	1.28	0.028
217814_at	CCDC47	1.28	0.032
<b>Combined</b>		<b>1.79</b>	<b>3.4e-07</b>

**Supplementary Table 2. Distant metastasis signature (4 genes): prognostic value of mitochondrial-related proteins up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (DMFS/ER(+)/N=1,395/>240-months).**

Probe	Symbol	HR (DMFS)	Log-rank test
201128_s_at	ACLY	1.72	3.1e-05
208845_at	VDAC3	1.66	1.2e-05
202282_at	HADH2	1.58	7.2e-05
201441_at	COX6B1	1.53	0.00017
<b>Combined</b>		<b>1.91</b>	<b>2.2e-08</b>

**Supplementary Table 3. Tumor recurrence signature (4 genes): prognostic value of mitochondrial-related proteins up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (RFS/ER(+)/N=3,082/>240-months).**

Probe	Symbol	HR (RFS)	Log-rank test
208845_at	VDAC3	1.56	2.3e-11
202282_at	HADH2	1.52	1.3e-09
201441_at	COX6B1	1.51	1.3e-10
201128_s_at	ACLY	1.12	0.091
<b>Combined</b>		<b>1.68</b>	<b>1.2e-15</b>

**Supplementary Table 4. Distant metastasis signature (9 genes): prognostic value of large mito-ribosomal proteins, evaluated in ER(+) breast cancer patients (DMFS /ER+)/N=1,395/>240-months).**

Probe	Symbol	HR (DMFS)	Log-rank test
218027_at	MRPL15	1.68	4.1e-06
218049_s_at	MRPL13	1.56	8.8e-05
222216_s_at	MRPL17	1.53	0.00044
219244_s_at	MRPL46	1.46	0.0013
217907_at	MRPL18	1.40	0.005
218281_at	MRPL48	1.38	0.0078
208787_at	MRPL3	1.37	0.0086
218270_at	MRPL24	1.33	0.021
218105_s_at	MRPL4	1.29	0.023
<b>Combined</b>		<b>1.59</b>	<b>5e-05</b>

**Supplementary Table 5. Tumor recurrence signature (9 genes): prognostic value of large mito-ribosomal proteins, evaluated in ER(+) breast cancer patients (RFS /ER+)/N=3,082/>240-months).**

Probe	Symbol	HR (RFS)	Log-rank test
218027_at	MRPL15	1.72	<1e-16
218049_s_at	MRPL13	1.71	<1e-16
208787_at	MRPL3	1.71	<1e-16
222216_s_at	MRPL17	1.70	1.1e-16
217907_at	MRPL18	1.55	2e-11
218281_at	MRPL48	1.26	0.00041
218105_s_at	MRPL4	1.24	0.00095
219244_s_at	MRPL46	1.21	0.0083
218270_at	MRPL24	1.10	0.2
<b>Combined</b>		<b>1.71</b>	<b>&lt;1e-16</b>

**Supplementary Table 6. Distant metastasis signature (6 genes): prognostic value of large mito-ribosomal proteins, evaluated in ER(+) breast cancer patients (DMFS /ER+)/N=618/>240-months) treated with Tamoxifen.**

Probe	Symbol	HR (DMFS)	Log-rank test
218027_at	MRPL15	2.15	1.7e-06
219244_s_at	MRPL46	1.99	0.00011
222216_s_at	MRPL17	1.99	0.0036
218270_at	MRPL24	1.94	0.00024
217907_at	MRPL18	1.71	0.0051
218049_s_at	MRPL13	1.55	0.021
<b>Combined</b>		<b>2.16</b>	<b>1.7e-05</b>

**Supplementary Table 7. Tumor recurrence signature (8 genes): prognostic value of large mito-ribosomal proteins, evaluated in ER(+) breast cancer patients (RFS /ER+)/N=799/>240-months) treated with Tamoxifen.**

Probe	Symbol	HR (RFS)	Log-rank test
218027_at	MRPL15	2.20	7.8e-08
208787_at	MRPL3	2.04	0.00015
222216_s_at	MRPL17	2.01	2.3e-06
217907_at	MRPL18	1.92	9.1e-06
218270_at	MRPL24	1.77	0.00012
218049_s_at	MRPL13	1.66	0.0059
218281_at	MRPL48	1.55	0.0033
219244_s_at	MRPL46	1.53	0.0063
<b>Combined</b>		<b>3.45</b>	<b>1.6e-08</b>

**Supplementary Table 8. Distant metastasis signature (6 genes): prognostic value of large mito-ribosomal proteins, evaluated in ER(-)/basal breast cancer patients (DMFS/N=145/>120-months).**

<b>Probe</b>	<b>Symbol</b>	<b>HR (DMFS)</b>	<b>Log-rank test</b>
222466_s_at	MRPL42	4.00	0.0024
227186_s_at	MRPL41	3.43	0.0023
225797_at	MRPL54	2.44	0.011
218049_s_at	MRPL13	2.23	0.0022
224331_s_at	MRPL36	2.13	0.036
218339_at	MRPL22	1.75	0.029
<b>Combined</b>		<b>2.95</b>	<b>0.0018</b>